Clear cell renal carcinoma

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

100Recruiting trials

Regulatory Watchboard

10 events

Aug 2026Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Gruppo Oncologico Italiano di Ricerca Clinica — PHASE2

TrialNOT YET RECRUITING

Jun 2026Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network — PHASE3

TrialNOT YET RECRUITING

Jun 2026Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

City of Hope Medical Center — PHASE2

TrialNOT YET RECRUITING

May 2026Lu-177 PSMA Treatment in Cell Renal Carcinoma

Ankara University — PHASE3

TrialNOT YET RECRUITING

May 2026UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

UTC Therapeutics Inc. — PHASE1

TrialNOT YET RECRUITING

Apr 2026Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

City of Hope Medical Center — PHASE1

TrialRECRUITING

Mar 2026Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

M.D. Anderson Cancer Center — PHASE1

TrialNOT YET RECRUITING

Mar 2026CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

Massachusetts General Hospital — PHASE2

TrialNOT YET RECRUITING

Mar 2026Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Karie Runcie — PHASE2

TrialRECRUITING

Mar 2026Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Clear cell renal carcinoma.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Torisel

(Temsirolimus)Orphan drug

Wyeth Pharmaceuticals, Inc.

12.1 Mechanism of Action Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12...

Approved May 2007FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

100 active trials

11Phase 3

38Phase 2

15Phase 1

5N/A

12Unknown

15PHASE1, PHASE2

4EARLY_PHASE1

100Total recruiting

Search clinical trials for Clear cell renal carcinoma →

Recent News & Research

No recent news articles indexed yet for Clear cell renal carcinoma.
Search PubMed for Clear cell renal carcinoma →

Browse all Clear cell renal carcinoma news →

Specialist Network

Top 6 by expertise

Pavlos Msaouel, M.D., Ph.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 382 trials2 pubs

Eric Jonasch, MD, M.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 3412 trials

Giuseppe Procopio, MD, R. Ph

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

📍 RAHWAY, NJ

Score 228 trials1 pub

Nizar M. Tannir, MD, M.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 203 trials

Wenxin Xu, MD, M.D

Dana-Farber Cancer Institute

📍 BOSTON, MA

Score 172 trials1 pub

Andrea B Apolo

National Cancer Institute LAO

📍 Birmingham, Alabama

Score 174 trials

View all Clear cell renal carcinoma specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles